PROM1 and colorectal carcinoma: A further study of CD133 in colorectal cancer (CRC) treated with asymmetric bispecific antibody (BiAb) consisting of CD133 and CD3 antibodies indicated strong anti-tumor efficacy (Zhao et al., 2015).